- GlobeNewswire•11 days ago
SALT LAKE CITY, March 14, 2017-- Lipocine Inc., a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present ...
- Zacks Small Cap Research•12 days ago
On March 6th Lipocine Inc. (LPCN) filed its 2016 10-K in conjunction with a press release highlighting 2016 achievements. For the year, Lipocine reported a net loss of $19 million and $1.04 per share which compares to our estimates of $20.4 million and $1.10 per share. Lower R&D and lower SG&A both contributed to the difference. We were under the impression that the trial costs related to the dosing validation (DV) study which began in December would cause a sequential jump in R&D expenses rather than a decline.
- GlobeNewswire•19 days ago
SALT LAKE CITY, March 06, 2017-- Lipocine Inc., a specialty pharmaceutical company, today announced financial and operational results for the full year ended December 31, 2016.. Initiated both a Dosing ...
LPCN : Summary for Lipocine Inc. - Yahoo Finance
Lipocine Inc. (LPCN)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.15 x 100|
|Ask||9.00 x 200|
|Day's Range||3.95 - 4.21|
|52 Week Range||2.51 - 12.66|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|